JP2006501252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501252A5 JP2006501252A5 JP2004533066A JP2004533066A JP2006501252A5 JP 2006501252 A5 JP2006501252 A5 JP 2006501252A5 JP 2004533066 A JP2004533066 A JP 2004533066A JP 2004533066 A JP2004533066 A JP 2004533066A JP 2006501252 A5 JP2006501252 A5 JP 2006501252A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- arylalkyl
- hydrogen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000219 mutagenic Toxicity 0.000 claims description 11
- 230000003505 mutagenic effect Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 claims description 6
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 4
- 102000003792 Metallothionein Human genes 0.000 claims description 4
- 108090000157 Metallothionein Proteins 0.000 claims description 4
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 3
- 235000019126 equol Nutrition 0.000 claims description 3
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000002537 cosmetic Substances 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 4
- 230000000475 sunscreen effect Effects 0.000 claims 3
- 239000000516 sunscreening agent Substances 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- -1 amino, thio Chemical group 0.000 claims 2
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000010586 diagram Methods 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- CNNBJLXLTIKXGJ-UHFFFAOYSA-N 3-phenyl-2h-chromene Chemical compound C1OC2=CC=CC=C2C=C1C1=CC=CC=C1 CNNBJLXLTIKXGJ-UHFFFAOYSA-N 0.000 description 1
- YJPJOELHSKMFPG-UHFFFAOYSA-N C=C(C(O1)=C)OC1=O Chemical compound C=C(C(O1)=C)OC1=O YJPJOELHSKMFPG-UHFFFAOYSA-N 0.000 description 1
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical group C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002951271A AU2002951271A0 (en) | 2002-09-06 | 2002-09-06 | Repair of dna mutagenic damage |
| PCT/AU2003/001152 WO2004022023A1 (en) | 2002-09-06 | 2003-09-05 | Repair of dna mutagenic damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501252A JP2006501252A (ja) | 2006-01-12 |
| JP2006501252A5 true JP2006501252A5 (https=) | 2006-10-26 |
Family
ID=27671591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004533066A Pending JP2006501252A (ja) | 2002-09-06 | 2003-09-05 | Ｄｎａ変異原性ダメージの修復 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060153781A1 (https=) |
| EP (1) | EP1534232A4 (https=) |
| JP (1) | JP2006501252A (https=) |
| CN (1) | CN1688285A (https=) |
| AU (1) | AU2002951271A0 (https=) |
| CA (1) | CA2497823A1 (https=) |
| CZ (1) | CZ2005136A3 (https=) |
| MX (1) | MXPA05002519A (https=) |
| NO (1) | NO20051605D0 (https=) |
| TR (1) | TR200500749T2 (https=) |
| WO (1) | WO2004022023A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104643057A (zh) | 2002-07-24 | 2015-05-27 | 儿童医院医疗中心 | 含有对映体牛尿酚的组合物和产物及其用途 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| WO2004039327A2 (en) | 2002-10-29 | 2004-05-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
| EP1542654A4 (en) * | 2002-09-23 | 2008-12-17 | Novogen Res Pty Ltd | TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| CA2738510A1 (en) * | 2008-07-30 | 2010-02-04 | Novogen Research Pty Ltd | 6-substituted isoflavonoid compounds and uses thereof |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| CN114831981A (zh) * | 2021-02-02 | 2022-08-02 | 上海交通大学 | 一种ERβ选择性激动剂在抗肿瘤中的应用 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| AUPP868599A0 (en) * | 1999-02-15 | 1999-03-11 | Novogen Research Pty Ltd | Production of isoflavone derivatives |
| DE10121375B4 (de) * | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
| DE10122342A1 (de) * | 2001-05-09 | 2002-11-14 | Beiersdorf Ag | Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen |
-
2002
- 2002-09-06 AU AU2002951271A patent/AU2002951271A0/en not_active Abandoned
-
2003
- 2003-09-05 EP EP03793484A patent/EP1534232A4/en not_active Withdrawn
- 2003-09-05 JP JP2004533066A patent/JP2006501252A/ja active Pending
- 2003-09-05 CN CNA038240114A patent/CN1688285A/zh active Pending
- 2003-09-05 CA CA002497823A patent/CA2497823A1/en not_active Abandoned
- 2003-09-05 TR TR2005/00749T patent/TR200500749T2/xx unknown
- 2003-09-05 US US10/526,830 patent/US20060153781A1/en not_active Abandoned
- 2003-09-05 CZ CZ20050136A patent/CZ2005136A3/cs unknown
- 2003-09-05 MX MXPA05002519A patent/MXPA05002519A/es active IP Right Grant
- 2003-09-05 WO PCT/AU2003/001152 patent/WO2004022023A1/en not_active Ceased
-
2005
- 2005-03-30 NO NO20051605A patent/NO20051605D0/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL401636A1 (pl) | Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna | |
| JP2005538072A5 (https=) | ||
| CA2362394A1 (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | |
| JP2006501252A5 (https=) | ||
| YU69003A (sh) | Aril i heteroaril urea chk1 inhibitori kao jedinjenja koja povećavaju osetljivost na radioterapiju i hemoterapiju | |
| ATE232520T1 (de) | Imidazolidin-4-on derivate verwendbar als antikrebsmittel | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| ATE238981T1 (de) | Antitumorwirkstoffe | |
| JP2015522551A5 (https=) | ||
| IL165763A0 (en) | Process for preparing 5-(1,3-oxazol-2-yl)benzoic acid derivatives | |
| BR9814055A (pt) | Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto | |
| WO2001032631A3 (en) | Heterocyclic cytotoxic agents | |
| Park et al. | Thiazol-4 (5H)-one analogs as potent tyrosinase inhibitors: Synthesis, tyrosinase inhibition, antimelanogenic effect, antioxidant activity, and in silico docking simulation | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| CA2461963A1 (en) | Cyclic amine compounds | |
| WO2004014906A3 (en) | Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
| DE60225943D1 (de) | Topoisomerase-giftmittel | |
| EP1109560A4 (en) | COMPOUNDS USEFUL AS AICARFT INHIBITORS | |
| JP2011518843A5 (https=) | ||
| CA2382654A1 (en) | Novel a-500359 derivatives | |
| DE60119514D1 (de) | Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentansäure |